Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
February 25, 2025 — Kadimastem and iTolerance achieve a significant milestone in the development of a potential cure for Type 1 Diabetes through successful completion of a pre-IND meeting with the FDA. Learn more about the innovative approach and collaborative efforts towards revolutionizing diabetes treatment.